MOLOGEN closes second quarter of 2006:
Important contracts closed and good prospects although revenues still low

In the first six months of 2006, MOLOGEN AG (ISIN DE0006637200) secured important contractual agreements and further developed its technology. Thanks to the continued good liquidity position, business prospects are considered to be excellent. The current license negotiations indicate a balanced result for the first eight months of 2006.

In the first half of 2006, MOLOGEN generated EBIT of -1.7 million EUR in the Consolidated Financial Statements prepared in line with IFRS. In the same period of the previous year, EBIT was -1.9 million EUR. The revenues are 0.5 million EUR, slightly above those of the same period of the previous year (0.4 million EUR). The earnings per share amount to -0.20 EUR as compared to -0.31 EUR in the first six months of 2005.

Download Half-year Report 2006

Press Releases

About MOLOGEN

MOLOGEN uses its proprietary DNA technologies to create and develop treatments for high-unmet-need illnesses. The main focuses are the unique and patented MIDGE and dSLIM technologies. Based on these platforms, MOLOGEN is developing DNA-based vaccines and therapeutics to prevent or cure a wide range of diseases.

Going public in 1998, MOLOGEN was one of the first German biotechnology companies to be floated on the stock exchange. The MOLOGEN shares are traded on the Geregelter Markt in Frankfurt.

Disclaimer concerning prognoses

Certain statements in this communication contain formulations or terms referring to the future or future developments, as well as negations of such formulations or terms, or similar terminology. These are described as forward-looking statements. In addition, all information in this communication regarding planned or future results of business segments, financial classification numbers, developments of the financial situation, or other financial or statistical data contains such forward-looking statements. The company cautions prospective investors not to rely on such forward-looking statements as certain prognoses of actual future events and developments. The company is neither responsible nor liable for these forward-looking statements. It is not responsible for updating such information, which only represents the state of affairs on the day of publication.

back to the overview